PA-298 Predicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modelling
Johanna Eriksson, Marylore Chenel, Stephen Robinson(Intel (United States)), Jean‐Yves Gillon(Drugs for Neglected Diseases Initiative), Vijay Satam(Drugs for Neglected Diseases Initiative India), Eric B. Sjogren(The University of Texas MD Anderson Cancer Center), Henri Caplain(Drugs for Neglected Diseases Initiative), Vishal Goyal(Chandigarh University), Isabela Ribeiro(Drugs for Neglected Diseases Initiative)
Cited by 0
Related Papers
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis
|BMC Public Health|2017|72